Tokyo Tape
Sign in
← PHC Holdings

Half-year report · HY

6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.4bn2025-04-01 → 2025-09-30Cons.Revenue IFRS
Revenue¥361.6bn2024-04-01 → 2025-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Operating income¥10.4bn2025-04-01 → 2025-09-30Cons.Operating profit loss IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Profit before tax¥941m2025-04-01 → 2025-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.8bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥559m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥10.5bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥692m2025-04-01 → 2025-09-30Cons.Profit loss IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Total assets¥525.8bnat 2025-09-30Cons.Assets IFRS
Total assets¥532.5bnat 2025-03-31Cons.Assets IFRS
Total assets¥525.4bnat 2024-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥379.8bnat 2025-09-30Cons.Liabilities IFRS
Total liabilities¥391.3bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥146.0bnat 2025-09-30Cons.Equity IFRS
Net assets / equity¥141.2bnat 2025-03-31Cons.Equity IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31vCons.Equity IFRS
Equity (owners)¥146.7bnat 2025-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥141.6bnat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥39.6bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥12.1bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.9bn2024-04-01 → 2025-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥4.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.5bn2024-04-01 → 2025-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥17.6bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2024-04-01 → 2025-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-4.422025-04-01 → 2025-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥83.132024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-4.422025-04-01 → 2025-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥82.582024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio27.9%at 2025-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio26.6%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingrevenue external2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥3.2bn
Diabetes Managementreportable segmentrevenue2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentrevenue external2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentsegment profit2025-04-01 → 2025-09-30¥9.3bn
Diagnostics And Life Sciencesreportable segmentrevenue2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentrevenue external2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentsegment profit2025-04-01 → 2025-09-30¥1.3bn
Healthcare Solutionsreportable segmentrevenue2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentrevenue external2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentsegment profit2025-04-01 → 2025-09-30¥3.0bn
—segment totalrevenue2025-04-01 → 2025-09-30¥170.5bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥170.5bn
—segment totalsegment profit2025-04-01 → 2025-09-30¥13.6bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 753
ItemContextValueUnit
Share capital IFRSPrior1YearInstant48623000000JPY
Share capital IFRSInterimInstant48781000000JPY
Capital surplus IFRSPrior1YearInstant42039000000JPY
Capital surplus IFRSInterimInstant42114000000JPY
Retained earnings IFRSPrior1YearInstant2991000000JPY
Retained earnings IFRSInterimInstant44000000JPY
Treasury shares IFRSPrior1YearInstant-568000000JPY
Treasury shares IFRSInterimInstant-568000000JPY
Other components of equity IFRSPrior1YearInstant48553000000JPY
Other components of equity IFRSInterimInstant56286000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant141639000000JPY
Equity attributable to owners of parent IFRSInterimInstant146658000000JPY
Non controlling interests IFRSPrior1YearInstant-468000000JPY
Non controlling interests IFRSInterimInstant-617000000JPY
Equity IFRSPrior1YearInstant141171000000JPY
Equity IFRSInterimInstant146041000000JPY
Liabilities and equity IFRSPrior1YearInstant532482000000JPY
Liabilities and equity IFRSInterimInstant525819000000JPY
Revenue IFRSPrior1InterimDuration173863000000JPY
Revenue IFRSInterimDuration173375000000JPY
Cost of sales IFRSPrior1InterimDuration92635000000JPY
Cost of sales IFRSInterimDuration93781000000JPY
Gross profit IFRSPrior1InterimDuration81227000000JPY
Gross profit IFRSInterimDuration79594000000JPY
Selling general and administrative expenses IFRSPrior1InterimDuration72071000000JPY
Selling general and administrative expenses IFRSInterimDuration70018000000JPY
Other income IFRSPrior1InterimDuration384000000JPY
Other income IFRSInterimDuration1073000000JPY
Other expenses IFRSPrior1InterimDuration166000000JPY
Other expenses IFRSInterimDuration337000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1InterimDuration-162000000JPY
Share of profit loss of investments accounted for using equity method IFRSInterimDuration67000000JPY
Operating profit loss IFRSPrior1InterimDuration9212000000JPY
Operating profit loss IFRSInterimDuration10378000000JPY
Finance income IFRSPrior1InterimDuration1414000000JPY
Finance income IFRSInterimDuration169000000JPY
Finance costs IFRSPrior1InterimDuration3215000000JPY
Finance costs IFRSInterimDuration9606000000JPY
Profit loss before tax IFRSPrior1InterimDuration7411000000JPY
Profit loss before tax IFRSInterimDuration941000000JPY
Income tax expense IFRSPrior1InterimDuration3389000000JPY
Income tax expense IFRSInterimDuration1634000000JPY
Profit loss IFRSPrior1InterimDuration4022000000JPY
Profit loss IFRSInterimDuration-692000000JPY
Profit loss attributable to owners of parent IFRSPrior1InterimDuration4100000000JPY
Profit loss attributable to owners of parent IFRSInterimDuration-559000000JPY
Profit loss attributable to non controlling interests IFRSPrior1InterimDuration-78000000JPY
Profit loss attributable to non controlling interests IFRSInterimDuration-133000000JPY
Basic earnings loss per share IFRSPrior1InterimDuration32.52
Basic earnings loss per share IFRSInterimDuration-4.42

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass